Induced Pluripotent Stem Cells (iPSCs)—Roles in Regenerative Therapies, Disease Modelling and Drug Screening

• Published in: Cells (Basel, Switzerland) Switzerland), 2021-09, Vol.10 (9), p.2319
• Main Authors: Aboul-Soud, Mourad A. M., Alzahrani, Alhusain J., Mahmoud, Amer
• Format: Article
• Language: English
• Subjects: Alzheimer's disease; Cardiomyopathy; Coronary artery disease; disease; DNA methylation; Drug screening; Efficiency; embryo; Embryo cells; Epigenetics; Fibroblasts; Heart diseases; induced pluripotent stem cells; Liver diseases; modelling; Neurodegenerative diseases; Pluripotency; Regenerative medicine; Review; Somatic cells; Spinal cord injuries; Stem cells; Transcription factors
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells10092319

The discovery of induced pluripotent stem cells (iPSCs) has made an invaluable contribution to the field of regenerative medicine, paving way for identifying the true potential of human embryonic stem cells (ESCs). Since the controversy around ethicality of ESCs continue to be debated, iPSCs have been used to circumvent the process around destruction of the human embryo. The use of iPSCs have transformed biological research, wherein increasing number of studies are documenting nuclear reprogramming strategies to make them beneficial models for drug screening as well as disease modelling. The flexibility around the use of iPSCs include compatibility to non-invasive harvesting, and ability to source from patients with rare diseases. iPSCs have been widely used in cardiac disease modelling, studying inherited arrhythmias, neural disorders including Alzheimer’s disease, liver disease, and spinal cord injury. Extensive research around identifying factors that are involved in maintaining the identity of ESCs during induction of pluripotency in somatic cells is undertaken. The focus of the current review is to detail all the clinical translation research around iPSCs and the strength of its ever-growing potential in the clinical space.